Researchers from IDIBAPS - Hospital Clínic lead the debate on new anticoagulants in the American Heart Association

New anticoagulant treatments are available which are easier to administer and follow than the classic Sintrom. This treatment is well established but requires a close control that would not be necessary with the new anticoagulants. Although these new drugs offer important benefits, two main drawbacks should be considered. The first is its high price and the second is the resistance to prescribe them because of the difficulty to reverse their action. Dr. Ginés Escolar and Dr. Ana Galan, researchers from the Hemotherapy and Hemostasis team at IDIBAPS - Hospital Clínic of Barcelona, discussed on this subject in an American Heart Association's online seminar.